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Summary The Indium-labelled somatostatin analogue pentetreotide has been successfully developed for
imaging of somatostatin receptor positive tumours. However there is significant renal tubular uptake of the
radiolabelled peptide, which can obscure upper abdominal tumours and would preclude its use for targeted
radiotherapy. The aim of this study was to determine whether amino acid infusion, which has been shown to
block renal tubular peptide reabsorption, diminishes renal parenchymal uptake of this radiolabelled analogue.
Eight patients being scanned with the "'In-labelled somatostatin analogue, pentetreotide, for localisation of
gastroenteropancreatic tumours received an infusion of synthetic amino acids. The ratio of isotope uptake in
kidney to that in spleen was assessed, and compared to the ratio for matched control patients, to determine if
amino acid infusion reduced renal parenchymal uptake of the radiopharmaceutical. The amount of isotope in
the urine was determined to ensure that any effect of the amino acid infusion was unrelated to changes in
clearance.
Infusion of amino acids significantly reduced renal parenchymal uptake of isotope at 4 h. There was a
non-significant increase in urinary clearance of isotope over the 4 h, consistent with reduced reuptake and a
lack of effect on glomerular filtration rate.
This technique, by preventing renal damage, may allow the use of this somatostatin analogue for local
radiotherapy, and could be of wider value in blocking tubular re-uptake of potentially nephrotoxic agents,
such as radiolabelled Fab fragments.
The "'In-labelled somatostatin analogue, pentetreotide, has
recently been developed for the imaging of somatostatin
receptor positive lesions, particularly gastroenteropancreatic
tumours. In healthy volunteers up to 90% of this radio-
labelled peptide is cleared by the kidney, 50% within the first
4.5 h. However by 4 h about 7% of the injected dose was
taken up into the renal parenchyma, and about 5% remained
at 48 h with a median absorbed dose of 0.45 mGy/MBq
(range 0.19-0.8), and this uptake reduces the sensitivity of
detection for small tumours located in the upper abdomen
(Krenning et al., 1992). Thus reduced renal uptake could
enhance imaging sensitivity, and, furthermore, allow the use
of analogues labelled with a P-emitting radionuclide, if these
were to become available, for local radiotherapy without the
risk of significant nephrotoxicity (Lamberts et al., 1991).
The infusion ofcertain amino acids, particularly lysine and
arginine, has been shown to block renal tubular peptide
reabsorption (Morgenson & S0lling, 1977). The amino acids
are thought to prevent binding between free positive amine
or guanidine residues in the peptide and negatively charged
sites on the surface of the renal tubule. Infusion of synthetic
amino acids has been used therapeutically in acute renal
failure (Abel et al., 1973), although there are conflicting
reports about its efficacy, with evidence that it can cause a
deterioration in renal function in some patients (Zager,
1987). Infusion of a variety of amino acids in rats decreased
glomerular filtration rate, the maximal effect being seen with
arginine (58% decrease) and lysine (68% decrease). It was
concluded that many amino acids are potentially nephro-
toxic, and may sensitise the kidney to other forms of damage
(Zager et al., 1983). However in man infusion of an amino
acid solution (Travasol) at a rate sufficient to cause a two-
fold elevation in plasma amino acid concentrations (0.043 ml
kg-' min-1) resulted in a 17% increase in glomerular filtra-
tion rate (GFR) and a 15% increase in renal plasma flow
(RPF). Since amino acids stimulate release of a number of
hormones with the potential for increasing RPF (e.g gluca-
gon and growth hormone), somatostatin was infused at the
same time as the amino acids, and this abolished the changes
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in RPF and GFR (Castellino et al., 1987).
The aim of the present study was to determine whether
amino acid infusion could reduce renal re-uptake of "'In-
labelled pentetreotide, and to demonstrate that this was by
reducing tubular re-uptake, rather than diminishing
glomerular filtration rate. Such a technique of tubular uptake
blockade could have widespread application in diminishing
renal uptake of other potentially nephrotoxic agents: a
similar phenomenon has been observed when magnesium is
given with gentamicin to rats, magnesium competing with
gentamicin for tubular binding sites and thus preventing
gentamicin induced renal failure (Wong et al., 1989).
Materials and methods
Sixteen patients who were being imaged with "'In-labelled
pentetreotide to localise a probable gastroenteropancreatic
tumour were matched for age, sex, serum creatinine, tumour
type and tumour bulk (Table I), and randomly allocated to
the control or treatment groups. All had normal renal func-
tion.
"'In-labelled pentetreotide was kindly donated by Mallinck-
rodt Diagnostica (Petten, Holland). Injection of "'In-labelled
pentetreotide was performed within 2h of conjugating the
indium and the peptide. The dose of "'In-labelled pente-
treotide administered varied from 90 to 110 MBq. The effec-
tive whole body dose equivalent is 8 mSv/100 MBq, and so
the maximum possible radiation dose was 8.8 mSv.
The amino acid preparation administered was Synthamin
14 without electrolytes, containing 4.93 g 1' lysine and
17.6gl-1 arginine and with a tonicity of 880mosml1', and
this was obtained from Clintec (Slough, Berks., UK).
Patients in the active group received this intravenously at a
rate of 500 ml h-' over 4 h commencing at the time of IIIIn-
labelled pentetreotide injection. All patients emptied their
bladder immediately prior to commencing the infusion, and
then voided at the end of the infusion to allow quantification
of the amount of radioisotope cleared by the kidney during
the infusion. Four hours after injection of the "'In-labelled
pentetreotide all patients underwent plantar imaging of the
upper abdomen using a gammacamera (Maxicamera IgE)
with a medium energy collimator. At 4 h the radioisotope is
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predominantly peptide-bound in both plasma and urine
(Krenning et al., 1992). The ratio of kidney uptake to spleen
uptake was assessed and quantified using a visual analogue
scale from 1 to 5 (1 - spleen much greater than kidney, 3 -
equal uptake, 5 - kidney much greater than spleen), in all
cases by one person (AMP) blinded to the patient details. In
four infused patients and their controls quantification was
also performed by region of interest (ROI) analysis. ROI
were drawn closely around the spleen and both kidneys.
Radioactivity was expressed as (i) total counts per ROI, and
(ii) as counts per pixel (unit area) for spleen and kidneys. The
data was non-parametrically distributed and was analysed
using a Mann Whitney U test. Results are expressed as
mean ± standard error of the mean (s.e.m.), and P<0.05 is
regarded as significant.
Results
Using the visual analogue scale there was a highly significant
57% decrease in renal parenchymal uptake of isotope, when
compared to spleen uptake, following amino acid infusion
(Table IT, Figure 1). There was close correlation between the
kidney:spleen ratio as determined by this method and that
calculated following ROI analysis (r = 0.98 for both methods
of ROI analysis).
The significant decrease in renal parenchymal uptake in the
infused patients was confirmed by quantification by counts
by ROI analysis (Table TIT). Using total counts analysis there
was a 66% reduction, and by counts per pixel analysis the
reduction was 46%. There was no significant difference in
splenic counts per pixel between the two groups (treated
86 ± 32 vs control 71 ± 45), even when adjusted for dose
administered (treated 0.83 ± 0.28 vs control 0.69 ± 0.39
counts/MBq) and there was little correlation between the
kidney:spleen ratio and the splenic uptake (r = -0.45).
The quantities of isotope in the urine collected during the
4 h post-injection were very similar in the two groups, with
63 ± 3% of the total dose cleared in the infused group and
61 ± 3% of the total dose cleared in the controls.
This study demonstrates that amino acid infusion, which is
thought to block renal tubular protein uptake, reduces the
uptake of "'In-labelled pentetreotide by the kidney relative to
the spleen. The similar uptake of isotope by the spleen in
both groups indicates that this is the result of decreased renal
a
b
Table I Patients characteristics
Control Infused
Age (years) 55.9± 13.7 (26-69) 46.8± 14.8 (27-69)
Sex 2M, 6F IM, 7F
Creatinine 76.9± 15.6 (61-111) 72.5± 14.1 (56-94)
(JLmol 1')
Tumour type 3 Carcinoid 4 Carcinoid
3 Insulinoma 1 Insulinoma
1 Gastrinoma 2 Gastrinoma
1 Non-functioning 1 Non-functioning
Table II Comparison ofrenal uptake to splenic uptake in control and
infused groups (mean±s.e.m.) using visual analogue scalea; bp = 0.001
vs control
Control Infused
3.7±0.4 1.6±0.2b
aVisual analogue scale: I Kidney<<Spleen, 2 Kidney<Spleen, 3
Kidney = Spleen, 4 Kidney>Spleen, 5 Kidney>>Spleen.
Table III Ratio of renal uptake to splenic uptake in control and
infused groups (mean±s.e.m [range]) by ROI analysis; ap = 0.02 vs
control
Control Infused
Total counts 2.03±0.76 0.69±0.1Oa
(1.00-4.25) (0.655-0.955)
Counts per pixel 1.36±0.18 0.73±0.09a
(0.985- 1.8) (0.485±0.94)
Figure 1 Indium 111-labelled pentetreotide scans of a, control
(visual analogue scale 5, kidney:spleen ratio 1.8) and b, infused
patients (visual analogue scale 1, kidney:spleen ratio 0.48) show-
ing uptake in kidney and spleen (arrowed).RENAL UPTAKE OF "'In-LABELLED PENETREOTIDE 1439
re-uptake of "'In-labelled pentetreotide. The urinary clear-
ance of isotope in the infused patients was marginally greater
than that in the control group, indicating that the decreased
renal uptake is due to blockade of the tubular uptake
mechanism rather than the result of impaired glomerular
filtration or attentuation of protein binding of the radio-
labelled analogue. Furthermore the increase in urinary clear-
ance of the isotope of about 2%, although not statistically
significant since it represents such a small proportion of the
total excreted dose (about 60% over the first 4 h), would be
consistent with the degree of blockade of tubular re-uptake
observed since the renal uptake is normally about 6% of the
total dose and the reduction with amino acid infusion is
about 50%.
Ninety percent of gastroenteropancreatic tumours carry a
high density of somatostatin receptors. This radiolabelled
analogue binds to these and thus effectively images these
tumours (Krenning et al., 1992; Lamberts et al., 1991). In the
future the analogue loaded with a P-emitting isotope could be
used to give local radiotherapy. Both these uses could be
enhanced by decreasing renal re-uptake: its sensitivity in
detecting small tumours in the upper abdomen may be in-
creased, and the reduced risk of damage to the renal paren-
chyma would make local radiotherapy more feasible.
The technique we have described could have more wide-
spread application as a renal cytoprotectant. Cytoprotectants
such as sodium thiosulphate, which reduces cisplatinum
induced renal tubular necrosis, and the sulphhydryl-contain-
ing compounds N-acetylcysteine and 2-mercaptoethanesulfo-
nate (Mesna), which block cyclophosphamide induced bladder
toxicity, can significantly increase the value of compounds
whose use is limited by toxicity towards normal tissue (Dorr,
1991). Infusion of amino acids could provide renal cytopro-
tection by blocking renal re-uptake of any toxic agents con-
taining peptide fragments. One such application would be in
the imaging and treatment of tumours using Fab fragments
linked to radioisotopes or chemotherapeutic agents (Larson,
1990). Blocking Fab fragment re-uptake by concurrent infu-
sion of amino acids would increase the target to non-target
ratio for imaging purposes, since there is significant renal
uptake: 6% ofthe total dose for "'In-OV-TL 3 F(ab')2 which
is used to image ovarian cancer (Buijs et al., 1992). Thera-
peutic use of Fab fragments coupled to P-emitting radioiso-
topes or drugs would be less toxic if amino acid infusion
could reduce nephrotoxicity from the coupled agents.
Furthermore inhibition of other tubular uptake mechan-
isms by appropriate receptor blockers has the potential to
reduce nephrotoxicity from a variety of sources. These could
include other radiolabelled compounds, such as DMSA,
which could then be used to deliver local radiotherapy to
mestatatic medullary carcinoma of the thyroid, chemothera-
peutic agents, such as cisplatinum, and drug overdoses.
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